UnknownNot Applicable

A Study of Co-infections of HIV-1 and Schistosoma Mansoni and Its Impact on Praziquantel Treatment Outcomes

Tanzania2,000 participantsStarted 2012-05

Plain-language summary

In this study, it is hypothesized that helminth infections modulate immune responses against HIV-1 infection resulting into increased HIV-1 multiplication, faster progression to AIDS and increased episodes of AIDS-related opportunistic infections. Furthermore, the effect of helminth infections on progression of HIV-1 infection is dependent on helminth infection intensity, host background immunity, nutritional status, demographic factors and socio-economic status. Also, treatment of helminth infections using praziquantel and albendazole among HIV-1 infected individuals will lead to reduction in HIV-1 viral loads, improvement of CD4+ counts, CD4+/CD8+ ratio and Hb levels, improved weight gain and reduction of episodes of HIV-1 related opportunistic infections. In addition, HIV-1 infection is associated with poor anthelminthic treatment outcome as compared to non-HIV infected individuals

Who can participate

Age range15 Years – 55 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Permanent residents and those who have lived in the village for more than 2 years. * HIV-1 positive individuals only those with CD4+ ≥ 400 cells/μl Exclusion Criteria: * HIV-1 positive individuals with CD4+ \< 350 cells/μl, * Those who are on antiretroviral therapy (ARV) * Pregnant women are excluded. * Participants with chronic diseases such as leukemia, tuberculosis and viral hepatitis

What they're measuring

The impact of Praziquantel in HIV-1 individuals co-infected with Schistosoma mansoni

Timeframe: 12 month follow-up

Trial details

NCT IDNCT01541631

SponsorCatholic University of Health and Allied Sciences

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2013-06